EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS‐CoV‐2 Main Protease Inhibitors

Maria Fesatidou, Anthi Petrou, Athina Geronikaki iD

Chemistry & Biodiversity · 2024-12 · 21 (12)

DOI: 10.1002/cbdv.202401697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 23.10.2024. Verfasst von Maria Fesatidou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Drug Design, SARS-CoV-2, Thiazolidines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HEAL-Link, Hellenic Academic Libraries Link.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HIV‐1 remains a major health problem worldwide since the virus has developed drug‐resistant strains, so, the need for novel agents is urgent. The protein reverse transcriptase plays fundamental role in the viruses’ replication cycle. FDA approved Delavirdine bearing a sulfonamide moiety, while thiazolidinone has demonstrated significant anti‐HIV activity as a core heterocycle or derivative of substituted heterocycles. In this study, thirty new thiazolidinone derivatives (series A, B and C) bearing sulfonamide group were designed, synthesized and evaluated for their HIV‐1 RT inhibition activity predicted by computer program PASS taking into account the best features of available NNRTIs as well as against SARS‐COV‐2 main protease. Seven compounds showed good anti‐HIV inhibitory activity, with two of them, C1 and C2 being better (IC 50 0.18 μΜ & 0.12 μΜ respectively) than the reference drug nevirapine (IC 50 0.31 μΜ). The evaluation of molecules to inhibit the main protease revealed that 6 of the synthesized compounds exhibited excellent to moderate activity with two of them (B4 and B10) having better IC 50 values (0.15 & 0.19 μΜ respectively) than the reference inhibitor GC376 (IC 50 0.439 μΜ). The docking studies is coincides with experimental results, showing good binding mode to both enzymes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Docking SimulationDrug DesignSARS-CoV-2ThiazolidinesReverse Transcriptase InhibitorsCoronavirus 3C ProteasesHIV-1HumansStructure-Activity RelationshipMolecular StructureHIV Reverse TranscriptaseProtease InhibitorsMicrobial Sensitivity TestsAntiviral AgentsAnti-HIV Agents

Stichwörter der Autor:innen

AIDSCOVIDHIV-1 reverse transcriptaseMolecular dockingSARS-CoV-2SulfonamidesSynthesis designThiazolidinone

Substanzen

ThiazolidinesReverse Transcriptase InhibitorsCoronavirus 3C ProteasesHIV Reverse Transcriptase3C-like proteinase, SARS-CoV-2Protease InhibitorsAntiviral AgentsAnti-HIV Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.

ORCID-Profile: Athina Geronikaki

Förderung

  • HEAL-Link
  • Hellenic Academic Libraries Link

Zitieren

APA

Fesatidou, M., Petrou, A., & Geronikaki, A. (2024). Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS‐CoV‐2 Main Protease Inhibitors. Chemistry & Biodiversity, 21(12). https://doi.org/10.1002/cbdv.202401697

Vancouver

Fesatidou M, Petrou A, Geronikaki A. Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS‐CoV‐2 Main Protease Inhibitors. Chemistry & Biodiversity. 2024;21(12). doi:10.1002/cbdv.202401697

BibTeX
@article{Fesatidou2024,
  author = {Fesatidou, Maria and Petrou, Anthi and Geronikaki, Athina},
  title = {Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS‐CoV‐2 Main Protease Inhibitors},
  journal = {Chemistry & Biodiversity},
  year = {2024},
  volume = {21},
  number = {12},
  doi = {10.1002/cbdv.202401697}
}
Kostenlos starten →